AUSTIN, Texas, Aug. 31, 2020 /PRNewswire/ — Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center are among the first in the world to participate in a clinical trial to evaluate a new intra-cardiac echocardiography catheter. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, […]
Other News
GEN inCode Announces Completion of £3M Institutional Foundation Fundraise
OXFORD, England, Sept. 1, 2020 /PRNewswire/ — GEN inCode UK Limited, the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the completion of a £3.0M institutional fundraise to internationally scale its products and technology. GEN inCode specializes in genetic risk assessment and the prediction of cardiovascular […]
Genesis MedTech Acquires World-first Drug-coated Balloon Technology with Next-generation Angioplasty Architecture for the Treatment of Peripheral Vascular Diseases
– Provides patients suffering from peripheral vascular diseases a safer and more effective treatment than traditional balloon angioplasty – DCB to become the future standard of care for superficial femoral artery treatment – Fast growing global market with estimated 13% CAGR, to reach around US$1billion by 2025 SINGAPORE, Aug. 31, 2020 /PRNewswire/ […]
Preventice Solutions Receives Frost & Sullivan Global Remote Cardiac Monitoring Company of the Year Award
Award reflects excellence in visionary innovation, performance, and customer impact MINNEAPOLIS, Sept. 1, 2020 /PRNewswire/ — Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), announced today it received the 2020 Frost & Sullivan Global Remote Cardiac Monitoring Company of the […]
CHF Solutions Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
EDEN PRAIRIE, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced today receipt of written notification from the Nasdaq Stock Market that it has granted the company’s request for an 180-day extension […]
Novoheart Holdings Inc. Reports Second Quarter 2020 Financial Results
VANCOUVER, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Business Highlights: […]
Biotricity Provides Quarter Update and Announces Continued Growth
Technology Revenues Surged in the Quarter Ended June 30, 2020 REDWOOD CITY, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced record results in its technology service revenues, demonstrating a continued pattern of improved growth for its first […]
Ontrak Announces NASDAQ Global Market Listing
SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that the company’s Common Stock has been listed on the NASDAQ Global Market. Ontrak shares will continue to trade under the ticker “OTRK.” Mr. Terren Peizer, the Company’s […]
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) being developed as a treatment […]
Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
HELP Study results, evaluating levosimendan in patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF), will be presented during a Late-Breaking Clinical Trial session during the HFSA Annual Scientific Meeting MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing […]



